Abstract: There is provided a method of guiding ions, comprising providing an ion guide comprising a plurality of electrodes, confining ions radially within said ion guide by applying one or more voltages to said plurality of electrodes, applying an orthogonal DC field along at least a portion of said ion guide in order to control the temperature of ions as they travel through said ion guide, and applying an electrostatic driving potential to said plurality of electrodes to urge ions along the axial length of the ion guide, wherein said electrostatic driving potential is applied in the form of a DC travelling wave potential or other transient DC potential.

Abstract: There is provided a method of guiding ions, comprising providing an ion guide comprising a plurality of electrodes, confining ions radially within said ion guide by applying one or more voltages to said plurality of electrodes, applying an orthogonal DC field along at least a portion of said ion guide in order to control the temperature of ions as they travel through said ion guide, and applying an electrostatic driving potential to said plurality of electrodes to urge ions along the axial length of the ion guide, wherein said electrostatic driving potential is applied in the form of a DC travelling wave potential or other transient DC potential.

Abstract: The present disclosure relates generally to a method of separating ions according to their ion mobility, comprising (i) accumulating a first population of ions in a first region of an ion mobility separator, (ii) separating said first population of ions according to their ion mobility in said first region of said ion mobility separator, and (iii) accumulating a second population of ions in said first region of said ion mobility separator whilst said first population of ions are being separated according to their ion mobility in said ion mobility separator.

Abstract: The present disclosure relates generally to a method of separating ions according to their ion mobility, comprising (i) accumulating a first population of ions in a first region of an ion mobility separator, (ii) separating said first population of ions according to their ion mobility in said first region of said ion mobility separator, and (iii) accumulating a second population of ions in said first region of said ion mobility separator whilst said first population of ions are being separated according to their ion mobility in said ion mobility separator.

Abstract: The present disclosure relates generally to a method of separating ions according to their ion mobility, comprising (i) accumulating a first population of ions in a first region of an ion mobility separator, (ii) separating said first population of ions according to their ion mobility in said first region of said ion mobility separator, and (iii) accumulating a second population of ions in said first region of said ion mobility separator while said first population of ions are being separated according to their ion mobility in said ion mobility separator.

Abstract: The present disclosure relates generally to a method of separating ions according to their ion mobility, comprising (i) accumulating a first population of ions in a first region of an ion mobility separator, (ii) separating said first population of ions according to their ion mobility in said first region of said ion mobility separator, and (iii) accumulating a second population of ions in said first region of said ion mobility separator whilst said first population of ions are being separated according to their ion mobility in said ion mobility separator.

Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.

Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.

Abstract: A controlled release dosage form with variable release rates comprising: 1) a bilayer or multilayer tablet core in which at least one of the layers contains one or more pharmaceutically active ingredients and at least one of the layers contains one or more rate controlling polymers; 2) a substantially insoluble casing extended over the tablet core covering the majority of tablet surface but leaving a portion of one layer of the table core exposed (exposed layer), the casing resulting from electrostatic deposition of a powder comprising fusible particles onto the tablet core and fusing the particles to form a thin film.

Abstract: A fast dissolving and taste masked sildenafil solid dosage form comprising: (i) sildenafil granules which granules comprise at least 45% by weight of a salt of sildenafil, a solubilisation inhibitor for said salt of sildenafil and optionally a sweetening agent and (ii) one or more disintegrants wherein the disintegrants or combination of disintegrants are present in the form of agglomerates having an average agglomerated particle size of at least 50 ?m, said agglomerates comprising at least 10% by weight of disintegrant.

Abstract: The use of an aqueous solution of citric acid and a highly water-soluble sugar as a binder for the granulation of tablet excipients.

Abstract: A fast disintegrating tablet comprising an active ingredient and one or more disintegrants characterised in that the tablet comprises agglomerates having an agglomerated particle size of at least 50 ?m, said agglomerates comprising at least 10% by weight of a superdisintegrant selected from croscarmellose cellulose, crospovidone and sodium starch glycollate and being free of active ingredient.

Abstract: A pharmaceutical dosage form comprising: a) a tablet core comprising a pharmaceutically active ingredient and one or more pharmaceutically active ingredient and one or more pharmaceutically acceptable adjuvants, the tablet core having a tensile strength of less than 38 N/cm2 before coating and fusion and b) a coating extending over at least 25% of the surface area of the tablet core, the coating resulting from deposition of a powder comprising fusible particles and fusing the particles to form a coating film, thereby providing the pharmaceutical dosage form with a greater hardness/crush strength than the tablet core. The tablet core may be formed by light compression with enables coated components and fragile components, such as capsules, to be used within the compression blend with little or no damage.

Abstract: A controlled release dosage form comprising: (i) a tablet core comprising a pharmaceutically active ingredient and one or more pharmaceutically acceptable matrix forming polymers, (ii) a substantially insoluble casing extended over the tablet core covering between 25 to 99% of the surface area of the tablet core, like for example covering only the major surfaces like in FIG. 1 or on major surface and the sidewells like in FIG. 2, the casing resulting from electrostatic deposition of a powder comprising fusible particles onto the tablet core and fusing the particles to form a thin film such that the said electrostatic coated tablet releases the active ingredient with a release profile of active ingredient for 0 to at least 50% by weight release of active ingredient defined by the equations y=k*tn in which y is the fraction of active ingredient released, k is the kinetic constant, t is time, n is the release exponent and n is the range 0.70 to 1.0 i.e. an approximately zero order release profile.

Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.

Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.

Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.

Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.

Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.